CELYSTRA Pharma identifies, licenses, and commercializes innovative therapies for rare and underserved diseases in Canada.
CELYSTRA Pharma has raised $14.7M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
CELYSTRA Pharma's investors include Investissement Quebec, Crédit Mutuel Equity.
CELYSTRA Pharma is headquartered in Montreal, Canada.
CELYSTRA Pharma identifies, licenses, and commercializes innovative therapies for rare and underserved diseases in Canada.
CELYSTRA Pharma is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CELYSTRA Pharma — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/celystra-pharma. Accessed September 30, 2026.
VCBacked. (2026). CELYSTRA Pharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/celystra-pharma
{{cite web |title=CELYSTRA Pharma — Funding & Investors |url=https://www.vcbacked.co/company/celystra-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated